Compare HPE & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HPE | WAT |
|---|---|---|
| Founded | 1939 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.5B | 22.5B |
| IPO Year | N/A | 1995 |
| Metric | HPE | WAT |
|---|---|---|
| Price | $24.43 | $376.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 15 |
| Target Price | $26.13 | ★ $390.67 |
| AVG Volume (30 Days) | ★ 28.9M | 559.4K |
| Earning Date | 12-04-2025 | 11-04-2025 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | N/A | ★ 3.82 |
| EPS | N/A | ★ 10.88 |
| Revenue | ★ $34,296,000,000.00 | $3,105,638,000.00 |
| Revenue This Year | $20.01 | $7.96 |
| Revenue Next Year | $5.35 | $6.32 |
| P/E Ratio | ★ N/A | $34.60 |
| Revenue Growth | ★ 13.84 | 6.90 |
| 52 Week Low | $11.97 | $275.05 |
| 52 Week High | $26.44 | $423.56 |
| Indicator | HPE | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 59.49 | 42.31 |
| Support Level | $23.39 | $372.93 |
| Resistance Level | $24.67 | $397.55 |
| Average True Range (ATR) | 0.93 | 9.27 |
| MACD | 0.15 | -4.19 |
| Stochastic Oscillator | 80.52 | 6.20 |
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment; it also has a high-performance computing business. HPE's stated goal is to be a complete edge-to-cloud company. Its portfolio enables hybrid clouds and hyperconverged infrastructure.
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.